Novavax Settles Vaccine Supply Agreement Dispute

Novavax ( (NVAX) ) has issued an announcement.

Novavax, Inc. and the UK Health Security Agency have reached a settlement to terminate their SARS-COV-2 Vaccine Supply Agreement, resolving disputes and releasing both parties from claims. Under the agreement, Novavax will refund $123.8 million to the UK, with payments spread over three years. This settlement offers a structured financial resolution while maintaining transparency for investors and stakeholders.

For detailed information about NVAX stock, go to TipRanks’ Stock Analysis page.